Pharma Sample Clauses
The 'Pharma' clause typically outlines specific terms and conditions that apply to pharmaceutical products or services within a contract. It may address regulatory compliance, quality standards, intellectual property rights, and responsibilities related to the manufacture, distribution, or sale of pharmaceuticals. For example, it could require adherence to Good Manufacturing Practices (GMP) or specify procedures for handling recalls. The core function of this clause is to ensure that all parties involved in pharmaceutical transactions meet industry-specific legal and quality requirements, thereby reducing risk and ensuring product safety and compliance.
Pharma. P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company's primary focus is on its lead product, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV). A.P. Pharma submitted a New Drug Application (NDA) to the FDA in May 2009 and received a Complete Response Letter in March 2010 that outlined several issues that would need to be addressed prior to FDA approval of APF530. The Company is in the process of preparing a resubmission to address the issues outlined in the Complete Response Letter.
Pharma. If the Property Developer obtains the Land Parcel at the Public Tendering and upon the receipt of the Compensation by ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇.▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇.▇ Pharma shall pay the Compensation to the Property Developer. If the Property Developer is unable to obtain the Land Parcel at the Public Tendering, Shijiazhuang No.4 Pharma shall refund the Fixed Income and all other payments made by the Property Developer (without interest) to the Property Developer within 7 working days from the Public Tendering. Shijiazhuang No.4 Pharma shall then be entitled to retain the Compensation received under the Land Repurchase Agreement. If the Property Developer does not participate in the Public Tendering of the Land Parcel, Shijiazhuang No.4 Pharma shall have the right to retain the Fixed Income. Save for the Fixed Income, Shijiazhuang No.4 Pharma shall not participate in the sharing of income or profits from the Project, nor shall it be responsible for the operational losses arising from the Project. The Property Developer shall be responsible for all the development works of the Project, including but not limited to project development and construction, operational management and sales and marketing. The Property Developer shall be responsible for all the funding and investments into the Project. Upon obtaining the Land Parcel, the Property Developer shall also be solely responsible for the development and operations of the Project. As all of the applicable percentage ratios calculated in accordance with the Listing Rules in respect of the disposal of the Land Parcel are less than 5%, the disposal does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.
Pharma. In the event that the products of oral solid dosage form of AND-9 are launched eventually, within ten years after the launch, Shijiazhuang No. 4 Pharma shall pay a sales commission to Zhengzhou University at a rate of 2% of sales revenue for every year after the product launch. The Agreement and the transactions contemplated thereunder do not constitute a notifiable transaction for the Company under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) nor a connected transaction under Chapter 14A of the Listing Rules. The Board of the Company is also pleased to announce that the Group has obtained the approval for production and registration for Ambroxol Hydrochloride and Sodium Chloride Injection (100ml) in upright polypropylene infusion soft bag from the CFDA. Ambroxol Hydrochloride is mainly used for treatment of respiratory diseases. It promotes mucus clearance and eases cough, and is under previous type 6 chemical drug. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. By order of the Board Chow ▇▇▇▇ ▇▇▇▇▇ Company Secretary Hong Kong, 5 March 2018
Pharma wHEALTH, organized under the laws of the Grand Duchy of Luxembourg as a mutual investment fund (fond commun de placement) (the "Fund"), has retained the Management Company to manage the Fund's assets and appoint such advisors in so doing, and the Management Company desires to engage the Advisor in rendering such services to the Fund.
Pharma. Global MENA LTD reserves the right to alter, suspend or discontinue any part (or the whole of) the Website including, but not limited to, any products and/or services available. These terms and conditions shall continue to apply to any modified version of the Website unless it is expressly stated otherwise.
1. Nothing in these terms and conditions will:
(a) limit or exclude our or your liability for death or personal injury resulting from our or your negligence, as applicable;
(b) limit or exclude our or your liability for fraud or fraudulent misrepresentation; or (c) limit or exclude any of our or your liabilities in any way that is not permitted under applicable law.
2. We will not be liable to you in respect of any losses arising out of events beyond our reasonable control.
3. To the maximum extent permitted by law, Pharma. Global MENA LTD accepts no liability for any of the following:
1. any business losses, such as loss of profits, income, revenue, anticipated savings, business, contracts, goodwill or commercial opportunities;
2. loss or corruption of any data, database or software;
3. any special, indirect or consequential loss or damage.
Pharma. The 2012 special 301 watch report of the US Trade of Representatives cites US industry concern over “the lack of transparency, fairness, and predictability of the PHARMAC pricing and reimbursement regime, as well as the negative access of the overall climate for innovative medicines in NZ”
Pharma. Global MENA LTD accepts no liability for any disruption or non-availability of the Website.